DNAtrix is a Texas-based biotechnology company founded by world-class physicians and scientists from the UCSF Helen Diller Comprehensive Cancer Center and MD Anderson Cancer Center. DNAtrix, Inc. is focused on the development of oncolytic virus technology for the treatment of cancer. DNAtrix’s lead product, delta24-RGD, is a next-generation adenovirus invented by company founders Dr. Juan Fueyo and Dr. Frank McCormick, and is designed to destroy cancer cells without harming normal tissue.

It is hoped that this therapy can be added to the arsenal of surgery, radiation and chemotherapy for the treatment of a variety of tumors.  The company launched its first human clinical trials in 2009 at the MD Anderson Cancer Center for the treatment of brain cancer. In 2016, DNAtrix was awarded both EU Orphan Medicine Designation and EMA Prime Designation, an initiative designed to accelerate approval of breakthrough therapies that target an unmet medical need.